Skip to content

GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology

  • GS010 confirmed as safe and well tolerated 2 years after a single
    unilateral intravitreal injection
  • Sustained improvement of visual acuity at 2 years of follow-up in LHON
    subjects with less than 2 years of visual loss prior to treatment

Paris, France, February 20, 2018, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN:
FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing
innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders,
today announced publication of detailed results from the Phase I/II clinical trial and long-term follow-up of
GS010 in Leber Hereditary Optic Neuropathy (LHON) patients in Ophthalmology, the journal of the
American Academy of Ophthalmology. The study demonstrated that GS010 (rAAV2/2-ND4) is safe and
well tolerated 2 years after a single unilateral intravitreal administration.

Please find attached the complete press release.


Source:  GenSight Biologics